Sinogen Pharmaceutical and Southern Medical University jointly establish a provincial-level postdoctoral innovation practice base

Recently, the Department of Human Resources and Social Security of Guangdong Province approved the list of the eighth batch of provincial-level postdoctoral innovation practice bases in 2023, and the Guangdong Province Postdoctoral Innovation Practice Base jointly established by Sinogen Pharmaceutical and Southern Medical University was included in it. The approval of this base will further increase the support and acceleration of postdoctoral work for Sinogen Pharmaceutical's independent innovative drug development.

About Sinogen Pharmaceutical

Sinogen Pharmaceuticals is a biopharmaceutical company jointly founded by four national high-level talents and experts, dedicated to the development of innovative biological anti-tumor drugs to meet the global demand for malignant tumor treatment market. Sinogen Pharmaceutical's independently developed oncolytic bacterial drug SalMet-Vec® is a first-in-class genetic engineering biological product that can accurately target and rapidly dissolve tumors. It carries specific methionine hydrolase through attenuated Salmonella carrier, depriving the necessary amino acids required for tumor growth, thus killing tumor and preventing tumor proliferation. It is an efficient and tumor-targeting product for broad-spectrum solid tumors.

Sinogen Pharmaceutical owns the complete intellectual property rights and global rights of SalMet-Vec® which has obtained 6 IND clinical trial approvals from the US FDA, Taiwan TFDA and Mainland China NMPA, and has obtained the FDA's Orphan Drug Designation(ODD) for the treatment of osteosarcoma, liver cancer and small cell lung cancer.

About Southern Medical University

Southern Medical University, formerly known as the First Military Medical University of the People's Liberation Army of China, was founded in 1951 and was designated as a national key university in 1979. It is the only medical college among the first five provincial high-level key construction universities in Guangdong Province, one of the first "ministerial provincial" co-construction medical colleges in China, one of the first eight universities to offer an eight year clinical medicine major (undergraduate and doctoral programs), and one of the first batch of pilot universities for the National Excellent Doctor Education and Training Program. The school has been selected for the Times Higher Education World University Rankings Top 500 for three consecutive years, and it was ranked in the top 400 global universities in 2023.